Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks

NCT03122262 is registered in ClinicalTrials.gov with Professor Francois Venter as lead sponsor.

NCT NCT03122262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03122262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
Lead sponsor
Professor Francois Venter
Phase
Phase 3
Overall status
Completed
Start date
January 16, 2017
Completion date
July 29, 2022
Enrollment
1,110 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection